Pharmaceutical Prices in the 21st Century
Editat de Zaheer-Ud-Din Babaren Limba Engleză Hardback – 18 dec 2014
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 467.64 lei 43-57 zile | |
Springer International Publishing – 23 aug 2016 | 467.64 lei 43-57 zile | |
Hardback (1) | 639.80 lei 43-57 zile | |
Springer International Publishing – 18 dec 2014 | 639.80 lei 43-57 zile |
Preț: 639.80 lei
Preț vechi: 752.70 lei
-15% Nou
Puncte Express: 960
Preț estimativ în valută:
122.44€ • 127.19$ • 101.71£
122.44€ • 127.19$ • 101.71£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319121680
ISBN-10: 3319121685
Pagini: 411
Ilustrații: X, 411 p. 37 illus., 34 illus. in color.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.77 kg
Ediția:2015
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
ISBN-10: 3319121685
Pagini: 411
Ilustrații: X, 411 p. 37 illus., 34 illus. in color.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.77 kg
Ediția:2015
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
Public țintă
Professional/practitionerCuprins
Introduction.- Reference pricing strategies.- Differential pricing.- Prices of vaccines.
Recenzii
“This book is a collection of national case studies about pharmaceutical pricing policy. … this book offers a wealth of examples to consider, especially for low- and middle-income countries that are in the process of changing or establishing health insurance programs. Having a consolidated reference source, such as this book, for academics interested in the field of policy analysis will obviously be very useful.” (Suzanne Rose Hill, PharmacoEconomics, Vol. 34 (3), March, 2016)
Textul de pe ultima copertă
The book is an essential, comprehensive text onglobal drug pricing and covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total;nineteenof which are case studieson an array of high, middle, and low income countries. The final three chaptersdiscussvalue-based pricing, innovation, prices and the pharmaceutical industry and the link betweenpharmaceutical policy and pricing. As the pharmaceutical market continues to expand, a number of pharmaceutical pricing strategies have been employed to control drug expenditures. The book explores this phenomenon further and willserve a valuable resource for policy makers, funders, social insurance institutions and drug companies.
About the author
Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious“Research Excellence Award” from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, www.joppp.org and can be reached at z.babar@auckland.ac.nz.
About the author
Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious“Research Excellence Award” from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, www.joppp.org and can be reached at z.babar@auckland.ac.nz.
Caracteristici
Provides overview of the global pharmaceutical pricing policies Covers pharmaceutical pricing strategies in 19 countries Provides specific chapters on value-based pricing, innovation, prices and the pharmaceutical industry and the link between pharmaceutical policy and pricing Includes supplementary material: sn.pub/extras